-37%

est. 2Y upside i

Healthcare

Rank

#3722

Sector

Biotechnology

Est. Liquidity

~2Y

Data Quality

Data: High

Natera is a publicly traded company (NASDAQ: NTRA) with a strong market position in genetic testing, particularly with its leading Signatera MRD test and Panorama NIPT.

Last updated: March 10, 2026

Bull (20%)+75%

Natera's Signatera test achieves widespread Medicare coverage and clinical adoption across multiple oncology indications, significantly expanding its MRD market share and driving revenue to $4.5B+ by 2028. Continued innovation in women's health and organ transplant, coupled with strong execution, justifies a valuation of $48B-$50B, representing a ~75% upside.

Base (45%)+15%

Natera maintains its leading position in NIPT and continues to grow Signatera in oncology, navigating competitive pressures from Guardant Health and Exact Sciences. Revenue grows steadily to $3.2B-$3.5B by 2028, with improving profitability, leading to a modest valuation increase to $32B-$34B, representing a ~15% upside.

Bear (35%)-40%

Intense competition from established players like LabCorp and Quest Diagnostics in women's health, and aggressive pricing/product launches from Guardant Health and Exact Sciences in oncology, erode Natera's market share and pricing power. Regulatory hurdles or clinical trial setbacks for new indications further dampen growth. Revenue growth slows, and valuation contracts to $16B-$18B, representing a ~40% downside.

Est. time to liquidity~2.0 years

Preference Stack Risk

low

Funding Intensity

1%

Natera has raised $152M in total funding against a $27.9B valuation, resulting in a funding intensity of 0.54%. For a publicly traded company, liquidation preferences are not applicable to common stock.

Dilution Risk

low

As a publicly traded, cash flow positive company with significant cash reserves, the immediate risk of dilution from needing further funding rounds is low.

Secondary Liquidity

active

As a NASDAQ-listed company (NTRA), Natera's common stock is actively traded on the public market.

Other — 163 roles

View all 163 open roles at Natera →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Natera's data — designed to show you've done your homework.

  • 1

    “Given the intense competition in the oncology MRD and NIPT markets from well-established players like Guardant Health, Exact Sciences, and LabCorp, how does Natera plan to defend and grow its market share over the next 2-3 years?”

  • 2

    “With 2026 revenue guidance in the mid-20% range, how does Natera plan to accelerate growth beyond this, particularly considering the significant TAM in oncology and women's health, and what are the key drivers for achieving consistent GAAP profitability?”

  • 3

    “Natera is a public company, but the job seeker is evaluating equity at the current valuation. How does the company communicate the long-term equity value proposition to employees, especially considering market volatility and recent insider selling?”

Community

Valuation Sentiment

Our model estimates -37% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.